Characterization of ACTN4 as a novel antiviral target against SARS-CoV-2
Miao Zhu(Nanjing University of Chinese Medicine), Wuxiang Guan(Chinese Academy of Sciences), Shuang Ding(Chinese Academy of Sciences), Chao Shan(Chinese Academy of Sciences), Haojie Hao(Wuhan Institute of Virology), Zhen Chen(Qingdao University), Haizhou Liu(Chinese Academy of Sciences), Kunpeng Liu(Guangxi University), Baocheng Yu(Chinese Academy of Sciences), Haibin Liu(Wuhan Institute of Virology), Huize Sun(Chinese Academy of Sciences), Jierao Ren(Chinese Academy of Sciences), Xueyan Zhang(Palace Museum), Kui Zhang(Chinese Academy of Sciences), Fang Huang, Yi Liu(Fudan University), Lishi Liu(First Affiliated Hospital of Heilongjiang University of Chinese Medicine)
Cited by 8
Related Papers
An adenovirus-vectored COVID-19 vaccine confers protection from SARS-COV-2 challenge in rhesus macaques
|Nature Communications|2020|247
Enhancer-associated long non-coding RNA LEENE regulates endothelial nitric oxide synthase and endothelial function
|Nature Communications|2018|178
Epithelial-mesenchymal transition: An emerging target in tissue fibrosis
|Experimental Biology and Medicine|2015|146
A multitope SARS-CoV-2 vaccine provides long-lasting B cell and T cell immunity against Delta and Omicron variants
|DOAJ (DOAJ: Directory of Open Access Journals)|2022|76
Extracellular RNA in a single droplet of human serum reflects physiologic and disease states
|Proceedings of the National Academy of Sciences|2019|69